Skip to main content
Premium Trial:

Request an Annual Quote

Biocept Nabs BCBS Texas In-Network Provider Agreement

NEW YORK (GenomeWeb) – Biocept said today that it has secured an in-network provider agreement with Blue Cross Blue Shield of Texas, the largest provider of health benefits in that state.

The agreement raises the number of patients with in-network access to Biocept's liquid biopsy tests to about 185 million, with some members having access via multiple plans, the company said. Biocept has steadily increased its menu of assays over the last year and currently offers tests for alterations in a variety of cancer-associated genes in both circulating tumor cells and circulating cell-free DNA.

"It is gratifying that health plans are seeing the value of our liquid biopsy approach for profiling and monitoring important cancer biomarkers," Biocept President and CEO Michael Nall said in a statement. "Partnering with health insurers is a major focus of our business strategy, as it may increase physician access to this non-invasive technology for their patients and provide timely adjudication of claims for patients.

He added that the agreement is an especially important one for Biocept as Texas is one of the firm's largest markets.

Biocept also announced a similar agreement with Blue Cross Blue Shield of Illinois last year, and has previously signed coverage agreements with a variety of preferred provider networks.



The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.